Hsiung 2015

Current Status of Trial
Completed
Study Aim
Treatment Dementia
Study Design
RCT
Blinding
Single-blind
Intervention type
Non-pharmacological
Intervention
Music//Waitlist
Dosage and Duration
This is a crossover study. One group received immediate music therapy (MT) for 10 (60 min) sessions over 10-12 weeks, followed by another 12-week period of waiting; while the other group waited for 12 weeks before they received their MT.
Absolute Number of Participants
27
Health Status/Diagnosis
Alzheimer Disease (AD)
Main Diagnostic Criteria
Clinical diagnosis of AD//NPI score of 5 or more
Unit of Allocation and/or Setting
Community Setting
Results publication date
July 2015
Primary outcomes
Neuropsychiatric symptoms by Neuropsychiatric inventory (NPI); Dementia status by and C-GIC (Clinical Global Impression of Change)
Other outcomes
<p>
Cognitive function by <span data-scayt_word="ADAS-Cog" data-scaytid="1">ADAS-Cog</span>; Agitation by Cohen Mansfield Agitation <span data-scayt_word="Inventiory" data-scaytid="2">Inventiory</span> (<span data-scayt_word="CMAI" data-scaytid="3">CMAI</span>); Dementia status by Global Deterioration Scale (<span data-scayt_word="GDS" data-scaytid="4">GDS</span>); Stress by Morning salivary <span data-scayt_word="cortisol" data-scaytid="5">cortisol</span>; Quality of life (for subject and caregiver) by <span data-scayt_word="QOL-AD" data-scaytid="6">QOL-AD</span></p>
Key Points
According to Hsiung 2015, "we found a significant drop in NPI after MT (-2.6) compared to an increase during the waiting period (+5.9, P=0.037), but no significant differences in C-GIC (P=0.23). There was also a significant lowering of morning salivary cortisol level (-0.15 ug/dL) during MT compared to the waiting period (+2.7, P=0.039). No significant differences were observed in the ADAS-Cog, CMAI, GDS, or QOL-AD for the subject or the caregiver. There was a significant sequence effect, suggesting some carry-over benefits in the immediate compared to the delay-start group." The conclusion was that "our findings suggest that MT has beneficial effects on managing behavioural symptoms in patients with AD and decreasing stress as measured by morning cortisol level. MT can be offered as a safe alternative to pharmacological treatment in managing AD patients with behavioural symptoms." Record information taken from the abstract.